Last reviewed · How we verify
Isatuximab SC-OBDS
At a glance
| Generic name | Isatuximab SC-OBDS |
|---|---|
| Also known as | SAR650984, Sarclisa |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ELISA in Relapsed/Refractory MM (PHASE2)
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE2)
- Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isatuximab SC-OBDS CI brief — competitive landscape report
- Isatuximab SC-OBDS updates RSS · CI watch RSS
- Sanofi portfolio CI